Back to Search
Start Over
Real-world use of therapeutic drug monitoring of CT-P13 in patients with inflammatory bowel disease: A 12-month prospective observational cohort study
- Source :
- Clinics and Research in Hepatology and Gastroenterology, Clinics and Research in Hepatology and Gastroenterology, Elsevier, 2020, 44, pp.609-618. ⟨10.1016/j.clinre.2019.11.008⟩
- Publication Year :
- 2020
- Publisher :
- HAL CCSD, 2020.
-
Abstract
- Summary Background Whether therapeutic drug monitoring (TDM) of infliximab should be implemented in daily practice is an ongoing controversy. Aims To assess the real-world use of TDM in an observational multicentre cohort study with consecutive patients with inflammatory bowel disease (IBD) treated with CT-P13. Methods Between September 2015 and December 2016, 364 patients with IBD were treated with CT-P13 in 13 gastroenterology departments and were followed up for 54 weeks. Disease activity, CT-P13 trough concentration and anti-CT-P13 antibody (ACA) were recorded. Results Steroid-free clinical remission rates at week 54 were 67.0% and 56.4% in patients with CD and UC, respectively. CT-P13 trough concentrations were measured in 70.7% of the patients. The mean CT-P13 trough concentration was 4.2 ± 4.3 μg/mL. The presence of ACA was observed in 53 (15.9%) patients. CT-P13 trough concentration was collected in a proactive approach in 62.8% of cases and in a reactive approach in 37.2%. Among patients who submitted to TDM, CT-P13 therapy was optimized in 88.7% of the reactive group and in 22.5% of the proactive group (P Conclusion In a real-world cohort of patients with IBD treated with CT-P13, more than two-thirds of the patients underwent TDM. CT-P13 optimization was much less common in the proactive approach than in the reactive approach.
- Subjects :
- Adult
Male
medicine.medical_specialty
Time Factors
[SDV]Life Sciences [q-bio]
Inflammatory bowel disease
Cohort Studies
03 medical and health sciences
0302 clinical medicine
Internal medicine
medicine
Humans
Trough Concentration
Prospective Studies
Crohn's disease
Hepatology
medicine.diagnostic_test
business.industry
Gastroenterology
Antibodies, Monoclonal
Middle Aged
Inflammatory Bowel Diseases
medicine.disease
Ulcerative colitis
Infliximab
3. Good health
Therapeutic drug monitoring
030220 oncology & carcinogenesis
Cohort
Female
030211 gastroenterology & hepatology
Drug Monitoring
business
Cohort study
medicine.drug
Subjects
Details
- Language :
- English
- ISSN :
- 22107401 and 2210741X
- Database :
- OpenAIRE
- Journal :
- Clinics and Research in Hepatology and Gastroenterology, Clinics and Research in Hepatology and Gastroenterology, Elsevier, 2020, 44, pp.609-618. ⟨10.1016/j.clinre.2019.11.008⟩
- Accession number :
- edsair.doi.dedup.....e77bb487b92f360087208613e087c9e8